ReviewAnnals of general psychiatry2024
Management of schizophrenia and comorbid substance use disorders: expert review and guidance.
Review in Annals of general psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genome-wide meta-analyses of cross substance use disorders in diverse populations.Molecular psychiatry · 2026Pooled it
- Brexpiprazole vs. Aripiprazole in Patients with Schizophrenia with or Without Comorbid Substance Use Disorder: A 12-Month Real-World Naturalistic Study of Efficacy.Brain sciences · 2026Article
- The Role of Social Contagion in Initiating Non-Suicidal Self-Injury in Schizophrenia: A Case Report.Actas espanolas de psiquiatria · 2026Article
- How clinicians think about dual disorders: Insights from a case vignette survey.Indian journal of psychiatry · 2026Article
- Concurrent (Dual) Disorder Management Guidelines: Systematic Review Update.Journal of clinical medicine · 2026Review
- Emerging Neurobiological and Therapeutic Insights into Schizophrenia: A Comprehensive Review.International journal of molecular sciences · 2026Review
- Romanian male patients with the dual diagnosis of schizophrenia and alcohol use disorder: a prospective study of clinical, social, and treatment-related factors affecting quality of life.Frontiers in psychiatry · 2026Article
- Clinical practice guidelines for management of schizophrenia in India: A comprehensive overview.Indian journal of psychiatry · 2026Article
- Prescriber- and Patient-Level Characteristics Associated with Patient Adherence to Any Antipsychotics Among Patients with Schizophrenia in the United States.Patient preference and adherence · 2026Article
- Treatment outcomes of an integrated treatment model for patients with co-occurring opioid use and schizophrenia spectrum disorders.Frontiers in psychiatry · 2026Article
- Managing schizophrenia with affective, sexual, metabolic and substance-use comorbidities: pharmacological considerations from an expert consensus.Annals of general psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia and substance use disorders (SUDs) are often comorbid conditions that present clinical challenges due to their heterogeneity and the difficulties associated with poor physical health, low medication adherence, high relapse and hospitalization rates, and increased risk of mortality. This is often exacerbated by a fragmented health care system that treats addiction and mental illness separately, leading to delays in proper diagnosis and treatment. MAIN TEXT: The aim of this narrative review, based on an extensive literature search and experts' clinical experience, is to synthesize evidence on the psychopathological and clinical characteristics of patients, the burden and management at the level of healthcare system, and possible gaps in the treatment of schizophrenia with comorbid SUD in order to understand and address the needs of patients. Treatment options, differences between antipsychotic medications, and the benefits of long-acting formulations and partial dopaminergic agonists are described. Partial dopamine agonists (aripiprazole, cariprazine, and brexpiprazole) have demonstrated good control of psychotic symptoms and SUDs with a favorable safety profile.
conclusionPharmacological interventions should be accompanied by psychosocial support within an integrated and multidisciplinary approach that promotes shared decision-making and a good therapeutic alliance between the entire medical team and the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.